Literature DB >> 26371746

Bendamustine reactivates latent Epstein-Barr virus.

Samantha G Fernandez1, J J L Miranda1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26371746      PMCID： PMC4944818          DOI： 10.3109/10428194.2015.1079317

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  15 in total

1.  Sequential use of paraformaldehyde and methanol as optimal conditions for the direct quantification of ZEBRA and rta antigens by flow cytometry.

Authors:  B M Imbert-Marcille; M Coste-Burel; N Robillard; J Foucaud-Gamen; S Billaudel; E Drouet
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

2.  Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab.

Authors:  Ricardo García Muñoz; Araceli Izquierdo-Gil; Aura Muñoz; Verónica Roldan-Galiacho; Pilar Rabasa; Carlos Panizo
Journal:  Ann Hematol       Date:  2014-06-21       Impact factor: 3.673

3.  Characterization of the BcLF1 promoter in Epstein-Barr virus.

Authors:  P J Chang; Y S Chang; S T Liu
Journal:  J Gen Virol       Date:  1998-08       Impact factor: 3.891

4.  Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors.

Authors:  Wen-hai Feng; Bruce Israel; Nancy Raab-Traub; Pierre Busson; Shannon C Kenney
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

5.  Induction of lytic Epstein-Barr virus (EBV) infection by synergistic action of rituximab and dexamethasone renders EBV-positive lymphoma cells more susceptible to ganciclovir cytotoxicity in vitro and in vivo.

Authors:  Masanori Daibata; Kentaro Bandobashi; Masayuki Kuroda; Shosuke Imai; Isao Miyoshi; Hirokuni Taguchi
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

Review 6.  Epstein-Barr virus: 40 years on.

Authors:  Lawrence S Young; Alan B Rickinson
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

7.  An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions.

Authors:  Aaron Arvey; Italo Tempera; Kevin Tsai; Horng-Shen Chen; Nadezhda Tikhmyanova; Michael Klichinsky; Christina Leslie; Paul M Lieberman
Journal:  Cell Host Microbe       Date:  2012-08-16       Impact factor: 21.023

Review 8.  Virally targeted therapies for EBV-associated malignancies.

Authors:  Bruce F Israel; Shannon C Kenney
Journal:  Oncogene       Date:  2003-08-11       Impact factor: 9.867

9.  Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

Authors:  Wen-hai Feng; Gregory Hong; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Authors:  Ian W Flinn; Richard van der Jagt; Brad S Kahl; Peter Wood; Tim E Hawkins; David Macdonald; Mark Hertzberg; Yiu-Lam Kwan; David Simpson; Michael Craig; Kathryn Kolibaba; Samar Issa; Regina Clementi; Doreen M Hallman; Mihaela Munteanu; Ling Chen; John M Burke
Journal:  Blood       Date:  2014-03-03       Impact factor: 22.113
View more
  3 in total

1.  Epstein-Barr virus latency type and spontaneous reactivation predict lytic induction levels.

Authors:  An T Phan; Samantha G Fernandez; Jessica J Somberg; Kristin M Keck; Jj L Miranda
Journal:  Biochem Biophys Res Commun       Date:  2016-04-16       Impact factor: 3.575

2.  Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data.

Authors:  Chad M Vanderbilt; Anita S Bowman; Sumit Middha; Kseniya Petrova-Drus; Yi-Wei Tang; Xin Chen; Youxiang Wang; Jason Chang; Natasha Rekhtman; Klaus J Busam; Sounak Gupta; Meera Hameed; Maria E Arcila; Marc Ladanyi; Michael F Berger; Snjezana Dogan; Ahmet Zehir
Journal:  J Mol Diagn       Date:  2022-03-22       Impact factor: 5.341

3.  Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps.

Authors:  Kristin M Keck; Stephanie A Moquin; Amanda He; Samantha G Fernandez; Jessica J Somberg; Stephanie M Liu; Delsy M Martinez; Jj L Miranda
Journal:  J Biol Chem       Date:  2017-06-06       Impact factor: 5.157
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.